Literature DB >> 31549282

Development and validation of a prognostic nomogram for the overall survival of patients living with spinal metastases.

Xiong-Gang Yang1,2, Jiang-Tao Feng2, Feng Wang2, Xin He1, Hao Zhang2, Li Yang2, Hao-Ran Zhang2, Yong-Cheng Hu3.   

Abstract

INTRODUCTION: The primary goal of treatment in spinal metastasis is typically to extend patients' lifespan as much as possible, and optimally to relieve the symptoms and so improve quality of life. It is crucial to avoid over- or under-treatment, according to each patient's individual situation. Thus, this study aimed to identify significant prognostic factors for patients living with metastatic spine disease, and create a new nomogram for the prediction of survival rates.
METHODS: Data from patients who had undergone operations for spinal metastasis between 2005 and 2016 were retrieved retrospectively, and randomized into training (70%) and validation groups (30%). A selection of pre-operative factors was analyzed using univariable and multivariable COX model for the training group. A nomogram was then developed using significant predictors in multivariable analysis. Accuracy was validated using a concordance index (C-index) and calibration curve for the training and validation groups, respectively.
RESULTS: A total of 244 participants were enrolled, including 171 in the training group and 73 in the validation group. Primary tumor, Frankel Grade, Karnofsky Performance Score (KPS) and adjuvant therapy were found to be significant for predicting survival rates. A nomogram was developed by utilizing these predictors. The C-indexes for the two groups were 0.711 and 0.703 respectively. Moreover, a favorable consistency between the predicted and actual survival probabilities was demonstrated using calibration curves.
CONCLUSIONS: A user-friendly nomogram model for facilitating medical procedures during clinical encounters was established to aid clinical decision making for individual patients.

Entities:  

Keywords:  Nomogram; Overall survival; Prognostic factor; Prognostic scoring system; Spinal metastasis

Mesh:

Year:  2019        PMID: 31549282     DOI: 10.1007/s11060-019-03284-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

1.  Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial.

Authors:  Roy A Patchell; Phillip A Tibbs; William F Regine; Richard Payne; Stephen Saris; Richard J Kryscio; Mohammed Mohiuddin; Byron Young
Journal:  Lancet       Date:  2005 Aug 20-26       Impact factor: 79.321

Review 2.  Bone metastasis and the metastatic niche.

Authors:  Guangwen Ren; Mark Esposito; Yibin Kang
Journal:  J Mol Med (Berl)       Date:  2015-08-15       Impact factor: 4.599

3.  Vertebral metastases: a critical appreciation of the preoperative prognostic tokuhashi score in a series of 71 cases.

Authors:  E A Enkaoua; L Doursounian; G Chatellier; F Mabesoone; T Aimard; G Saillant
Journal:  Spine (Phila Pa 1976)       Date:  1997-10-01       Impact factor: 3.468

4.  A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease.

Authors:  Paul Klimo; Clinton J Thompson; John R W Kestle; Meic H Schmidt
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

5.  The Oswestry Risk Index: an aid in the treatment of metastatic disease of the spine.

Authors:  B Balain; A Jaiswal; J M Trivedi; S M Eisenstein; J H Kuiper; D C Jaffray
Journal:  Bone Joint J       Date:  2013-02       Impact factor: 5.082

6.  Do elderly patients benefit from surgery in addition to radiotherapy for treatment of metastatic spinal cord compression?

Authors:  D Rades; S Huttenlocher; J N Evers; A Bajrovic; J H Karstens; V Rudat; S E Schild
Journal:  Strahlenther Onkol       Date:  2012-02-16       Impact factor: 3.621

7.  Anterolateral decompression for metastatic epidural spinal cord tumors. Results of a modified costotransversectomy approach.

Authors:  M C Overby; A S Rothman
Journal:  J Neurosurg       Date:  1985-03       Impact factor: 5.115

8.  Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival.

Authors:  Ahmedin Jemal; Limin X Clegg; Elizabeth Ward; Lynn A G Ries; Xiaocheng Wu; Patricia M Jamison; Phyllis A Wingo; Holly L Howe; Robert N Anderson; Brenda K Edwards
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

9.  The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death.

Authors:  L Leon Chen; Matthew E Nolan; Melvin J Silverstein; Martin C Mihm; Arthur J Sober; Kenneth K Tanabe; Barbara L Smith; Jerry Younger; James S Michaelson
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

Review 10.  Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.

Authors:  Gary S Collins; Johannes B Reitsma; Douglas G Altman; Karel G M Moons
Journal:  BMJ       Date:  2015-01-07
View more
  3 in total

1.  Predictive Model and Risk Factors for Case Fatality of COVID-19: A Cohort of 21,392 Cases in Hubei, China.

Authors:  Ran Wu; Siqi Ai; Jing Cai; Shiyu Zhang; Zhengmin Min Qian; Yunquan Zhang; Yinglin Wu; Lan Chen; Fei Tian; Huan Li; Mingyan Li; Hualiang Lin
Journal:  Innovation (N Y)       Date:  2020-08-03

2.  Bisphosphonates May Reduce Intraoperative Blood Loss in Surgery for Metastatic Spinal Disease: A Retrospective Cohort Study.

Authors:  Hao-Ran Zhang; Yun-Long Zhao; Rui-Qi Qiao; Ji-Kai Li; Yong-Cheng Hu
Journal:  Clin Interv Aging       Date:  2021-11-01       Impact factor: 4.458

3.  Nomogram for Predicting the Postoperative Venous Thromboembolism in Spinal Metastasis Tumor: A Multicenter Retrospective Study.

Authors:  Hao-Ran Zhang; Ming-You Xu; Xiong-Gang Yang; Feng Wang; Hao Zhang; Li Yang; Rui-Qi Qiao; Ji-Kai Li; Yun-Long Zhao; Jing-Yu Zhang; Yong-Cheng Hu
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.